Acute Myeloid Leukemia and Myeloid Neoplasms
The sponsor supports research in acute myeloid leukemia across both treatment-naive and relapsed settings, with interest in molecularly defined disease such as FLT3-mutated AML and IDH1-mutated AML. Its portfolio also includes work in blastic plasmacytoid dendritic cell neoplasms, reflecting a focus on aggressive hematologic malignancies.
- FLT3-mutated acute myeloid leukemia
- IDH1-mutated acute myeloid leukemia
- Blastic plasmacytoid dendritic cell neoplasms
- Post-remission therapy in AML
These studies place emphasis on disease control in older adults and on biologically targeted approaches within myeloid cancer care.
Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The sponsor funds multiple trials in chronic lymphocytic leukemia, including symptomatic disease, high-risk early-stage disease, and frail or elderly populations. Related research extends to small lymphocytic lymphoma, with attention to treatment sequencing and long-term disease management.
- Previously untreated symptomatic CLL
- High-risk stage A CLL
- Elderly patients with CLL or SLL
- High-risk biologic CLL features
Key interests include B-cell malignancy treatment strategies, fixed-duration therapy, and approaches for patients with limited physiological reserve.
Richter Syndrome and Aggressive Lymphoma Transformation
Research activity also covers Richter syndrome, focusing on the transformation of chronic lymphocytic leukemia into aggressive diffuse large B-cell lymphoma. This area reflects interest in high-risk lymphoid transformation and frontline treatment options for advanced disease.
- Previously untreated Richter syndrome
- Diffuse large B-cell lymphoma histology
- Transformed CLL
The sponsor’s work in this domain addresses a clinically challenging form of lymphoma with urgent therapeutic need.
Waldenström Macroglobulinemia
The portfolio includes studies in Waldenström macroglobulinemia after prior treatment, indicating interest in indolent B-cell lymphoproliferative disorders and their relapsed disease settings.
- Previously treated Waldenström macroglobulinemia
- Relapsed B-cell neoplasms
This area adds further breadth to the sponsor’s focus on mature lymphoid malignancies.
